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Observations of the Site-Specific
Carcinogenicity of Vinyl Chloride
to Humans
by Peter F. Infante*
A review of epidemiologic studies of workers exposed to vinyl chloride (VC) was conducted.
Some of these studies comprised small cohorts and thus were insensitive in the evaluation
of carcinogenic response for sites that do not demonstrate a high relative risk. Other larger
studies used methodology and design that precluded an interpretation of the results. Such
limitations were acknowledged by some authors.
Use of restrictive disease rubrics also lead to the submerging of sites that would have
demonstrated significant excesses. For example, some investigators analyzed data for liver
cancer deaths with the board category ofdigestive system cancer deaths, while others combined
data for CNS cancer deaths with the broad cateogry of"other and unspecified cancer," and most
studies analyzed information for lymphatic and hematopoietic system cancer deaths with all
datacombined. Onlyfourofeight studies reviewed could demonstrate a significant excess ofliver
cancer among VC-exposed workers-a site confirmed in humans by 1974. In contrast, five of
eight studies appear to demonstrate a significant excess of CNS cancer mortality. Workers
exposed to VC also demonstrate a significant excess ofmortality for lung cancer, while the data
for lymphatic and hematopoietic system cancer are suggestive. Interpretation of cancer of the
latter systems may have been clarified if investigators had not analyzed their data by broad
disease classifications.
In 1930, shortly after vinyl chloride (VC) was
introduced into commerce, VC toxicity was re-
ported in experimental animals (1). Over the next
five decades, study throughout the world indicated
that employment in the VC industry was associated
with a wide range of toxicity in humans. This
toxicity has included nonmalignant pathologic ef-
fects or symptoms, involving (but not limited to)
the bones, liver, central nervous system (CNS),
lungs, and blood (2).
Between 1970 and 1974, experimental bioassay
demonstrated VC-induced cancer in multiple or-
gans including the liver, brain, lungs and lymphatic
system (3, 4). This carcinogenic response has been
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observed in several species, given a wide range of
doses, by various routes of administration.
Between 1973 and 1977, several epidemiologic
studies were undertaken to assess the site-specific
cancerrisk amongworkers exposed to VC. Forthis
presentation, findings of these studies will be
limited to an assessment ofcancer offour organs or
organ systems in humans. These same sites are
known to be associated with nonmalignant VC-
related disease or symptoms in humans and cancer
in experimental animals.
Liver Cancer in Humans
Table 1 shows a summation of data from the
epidemiologic studies as related to liver cancer.
Some authors did not present site-specific analyses
forliver cancerdeaths. Therefore, the most specific
information available is presented.
Waxweiler et al. (5) conducted a cohort study of
workers who had been exposed to VC in the U.S.
89Table 1. Epidemiologic study results of VC-exposed workers as related to biliary and liver or digestive system cancer deaths.
Deaths
Investigation Site Observed Expected SMR
Waxweiler et al. (5) Biliary and liver
Total cohort 7 0.6 1155a
Latency > 15 yr 7 0.4 1606a
Byren et al. (6) Liver and pancreas
Total cohort 4 0.97 413
Latency > 10 yr 4 0.68 589a
Fox and Collier (7) Liver
Total cohort 4 1.64 244
Plant #2 > 15 yr 3 0.13 2308a
Seven other plants 1 1.51 66
Monson et al. (8) Biliary and liver
Total deaths 8 0.7
Tabershaw and Gaffey (9) Digestive organs
Total cohort 19 21.7 94
Highest exposure,
> 5 yr employment 11 7.5 151
Buffier et al. (10)d
Ott et al. (11)e
EEH (12) Digestive organs
Total cohort 29 40.8 71
Latency > 20 yr 9 13.6 70
ap < 0.01. bp < 0.05.
'Proportional mortality study risk ratio.
dNo liver cancer identified among 8 cancer deaths.
eNo liver cancer identified among 20 cancer deaths.
for at least five years and who had achieved a
period of ten or more years since initial exposure
(latency). On the basis of seven liver and biliary
cancer deaths that fit the cohort definition, the
study demonstrated an 11-fold to 16-fold excessive
risk of death from cancer of this site among
VC-exposed workers. These findings represent an
underestimate ofthe risk because seven additional
individuals who died from liver/biliary cancer at the
plants being studied were not included in the
analyses. Ofthese latter seven cases, four individu-
als diagnosed with liver angiosarcoma were still
alive atthe study cut-offdate, while twoindividuals
who died from biliary cancer had incomplete infor-
mation on length of exposure to VC. A seventh
individual did not fit the study cohort definition as
he was exposed for only three years. He died from
liver angiosarcoma 17 years after his initial expo-
sure to VC.
Byren et al. (6) conducted a cohort study of all
Swedish workers ever employed in positions where
exposure to VC could have occurred. The investi-
gators combined deaths from cancer ofthe liverand
pancreas because they believed that there was
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some overlap in reporting. There were four
liver/pancreatic cancer deaths observed, compared
to 0.77 expected (p < 0.02). An additional death
from liver angiosarcoma was identified as having
occurred after the study cut-off date and thus was
not included in the study.
Fox and Collier (7) studied U.K. workers ex-
posed to VC. In eight factories studied, they
observed a total of four liver cancer deaths as
compared to 1.64 expected. Three of these deaths
occurred in factory 2, where only 0.13 would have
been expected (p < 0.01). The authors stated thatit
was difficult to identify angiosarcoma of the liver
from death certificates (the usual method of
identification), since some of these deaths were
classified as primary, some as secondary liver
cancer, and others were not certified as cancer
deaths at all.
The results from the Fox and Collier study
probably represent an underestimate of the ob-
served risk of death from cancer for the following
reasons: (1) 75% ofthe study cohort was employed
for less than ten years; (2) only 8% of the cohort
was employed for more than 20 years; and (3) even
Environmental Health Perspectivesfor those who completed 20 years of service, the
authors stated that "because their service has only
recently been completed, the follow-up period is too
short to evaluate the carcinogenic effect of VCM."
This statement obviously applies to the liver as well
as to other sites.
Monson et al. (8) conducted a proportional mor-
tality study of 161 deceased workers from two
plants where VC was used. These plants were also
studied by Waxweiler et al. (5). They observed
eight deaths from liver and biliary tract cancer
versus 0.7 expected; the risk ratio was 11.0.
Tabershaw and Gaffey reported the results of a
cohort study of workers exposed to VC in 33 U.S.
industrial facilities. The authors did not analyze the
data separately for liver and biliary cancer. Thus,
deaths for these causes are accounted for in the
category of digestive organ cancer. As noted in
Table 1, for the total cohort there were 19 deaths
from digestive organ cancer and 21.7 expected. For
the highest exposure cohort, with more than five
years of exposure, there were 11 digestive organ
cancer deaths observed versus 7.5 expected. None
of the observations are statistically significant.
However, the risk ofliver cancer in this cohort is
submerged by including data for this cause ofdeath
in the analysis with digestive organ cancer deaths.
Of the 19 digestive cancer deaths, the authors
noted that seven were from liver cancer. Two of
these liver cancer deaths were listed as angiosarcoma
according to the diagnosis on the death certificate.
An additional four deaths from liver angiosarcoma
were identified in this cohort by the time the study
was published in 1974. Two of these deaths had
been categorized by death certificate diagnosis as
primary liver cancer, and two had been certified
under causes of death other than cancer, i.e.,
cirrhosis of the liver and hepatoma.
This study again demonstrates one of the inher-
ent limitations of epidemiologic studies (incorrect
diagnosis in relatively rare causes of death) that
result in an underestimate of the relative cancer
risk. An additional factor, indicated bythe authors,
that may have led to an underestimate ofthe risk in
this study was that the group with no vital status
determination, 15% of the population, began their
exposure ten years before the group for whom
followup was completed. As a result, some individ-
uals with longer latency periods were omitted from
the study. In addition, 57% of the cohort actually
studied had less than 15 years of latency. Because
ofthe healthy worker effect, the authors appropri-
ately stated that SMRs higher than expected may
be worthy ofattention even ifthey are not statisti-
cally significant.
Buffler et al. (10) and Ott et al. (11) did not
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observe any liver cancer deaths among eight and
twenty deaths, respectively, in their studies.
An unpublished study conducted by Equitable
Environmental Health (12) reported the mortality
of a cohort of workers from 37 U.S. industrial
facilities. This study included data for the facilities
studied by Tabershaw and Gaffey (9). Data were
not analyzed separately for liver cancer. However,
the category of death from cancer of the digestive
organs, which includes liver cancer deaths, indi-
cates a deficit of mortality. As shown in Table 1,
even for those individuals who had achieved 20 or
more years of latency, the SMR was only 70. It is
somewhat unusual to observe such a deficit of
mortality among workers who had achieved such a
long latency period.
Brain Cancer in Humans
Brain cancer also has been associated with expo-
sure to VC. A summary of the results of mortality
studies is shown inTable 2. Although the numberof
cases upon which observations were based are
small, Waxweiler et al. (5) and Byren et al. (6)
demonstrated significant excesses of brain cancer.
The relative risks were five and six, respectively.
Waxweiler et al. (5) also noted an unusual distribu-
tion in the cell type of brain cancer. Of 10 brain
cancer deaths identified among the VC-exposed
workers, nine (90%) had a histologic diagnosis of
glioblastoma multiforme. The tenth case had no
confirmation of cell type. The authors contrasted
this high proportion with that of the Yale autopsy
series in which 33% of primary intracranial neo-
plasms were glioblastoma multiforme.
Fox and Collier (7) observed two brain cancer
deaths as compared to 3.7 expected for the entire
cohort. For those cohort members categorized as
having high exposure, one brain cancer death was
observed versus 0.4 expected. Monson et al. (8)
demonstrated a fourfold risk of brain cancer.
Tabershaw and Gaffey (9) categorized brain can-
cer with "other and unspecified causes of cancer
death;" therefore, it is not possible to determine the
actual brain cancer risk identified in this study.
Since the Tabershaw and Gaffey study (9) was a
subset ofthe EEH study (12), the latter study was
used to estimate the expected number of brain
cancer deaths in the former study under the as-
sumption that the age distributions were similar.
The proportion of expected brain cancer deaths
from "other and unspecified cancer deaths" in the
EEH study (12) was then applied to the expected
from this same category in the Tabershaw and
91Table 2. Epidemiologic study results of VC-exposed workers as related to central nervous system.
Deaths
Investigation Site Observed Expected SMR
Waxweiler et al. (5) Brain and CNS
Total cohort 3 0.9 329
Latency > 15 yr 3 0.6 498a
Byren et al. (6) Brain
Total cohort 2 0.3 612a
Fox and Collier (7) Brain
Total cohort 2 3.7 55
Highest exposure 1 0.4 278
Monson et al. (8) Brain
Total deaths 5 1.2 4.2a,b
Tabershaw and Gaffey (9) Other and unspecified
Total cohort 17 11.8 155
Highest exposure,
> 5 yr employment 7 3.5 204
All exposure levels Brain 6 2.4c 250a
Buffier et al. (10)d
Ott et al. (11) All sites other than
Total cohort digestive and respiratory 6 6.8 88
Total cohort Brain 2 0.7c 286
EEH (12) Brain and CNS
Total cohort 12 5.9 203a
ap < 0.05.
bProportional mortality study risk ratio.
CEstimated.
dNo brain cancer identified among 8 cancer deaths.
Gaffey study (9). As a result, 2.4 brain cancer
deaths were estimated to have been expected and
compared to sixobserved inthe study. This difference
is significant.
Buffier et al. (10) did notidentify any deaths from
brain cancer in their small cohort. Ott et al. (11) did
not analyze their data separately for brain cancer,
but rather included brain cancer deaths with cancer
deaths from "all sites other than digestive and
respiratory." Therefore, using an analytical tech-
nique similar to that described above, the propor-
tion of expected brain cancer deaths among "all
sites otherthan digestive and respiratory" fromthe
EEH study (12) was applied to the expected in the
study by Ott et al. (11). As shown in Table 2, there
was a resultant estimated 0.7 brain cancer deaths
expected as compared to two observed. The excess
risk is estimated to be about threefold. The EEH
study (12) also demonstrates a significant excess
brain cancer among workers occupationally ex-
posed to VC. In summary, the dataforbrain cancer
appear to be more consistent between studies than
the data for liver cancer, although the magnitude of
the excessive risk is not as great for brain cancer.
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Lung Cancer in Humans
As shown in Table 3, Waxweiler et al. (5)
observed 11 lung cancer deaths as compared to 5.7
expected (p < 0.005) for cohort members who had
achieved 15 or more years of latency. The authors
also noted what appeared to be an unusual distribu-
tion in the histologic types oflung cancer. Ofeight
histologically confirmed lung cancer cases, five
were classified as large cell undifferentiated, and
three were categorized as adenocarcinoma. These
cell types are different from those usually associ-
ated with a cigarette smoking etiology, i.e., small
cell undifferentiated and epidermoid carcinomas.
With the exception of the study by Fox and
Collier (7), the remaining studies show excess risks
of lung cancer ranging from 7 to 200%. However,
the reservationexpressed by Fox and Collier(7), as
mentionedearlier, aboutthe shortperiod offollowup
limits the interpretation of their study. This con-
cern is supported by the observation that the SMR
for total mortality was only 75, 75% ofwhat would
be expected on the basis of comparison to the
standard population.
Environmental Health PerspectivesTable 3. Epidemiologic study results of VC-exposed workers as related to respiratory system cancer deaths.
Deaths
Investigation Site Observed Expected SMR
Waxweiler et al. (5) Respiratory
Total cohort 12 7.7 156
Latency > 15 yr 11 5.7 194a
Byren et al. (6) Lung
Total cohort 3 1.8 168
Fox and Collier (7) Lung
Total cohort 46 51.2 90
Highest exposure 2 3.7 54
Monson et al. (8) Lung
Total deaths 13 7.9 1.6b
Tabershaw and Gaffey (9) Respiratory
Total cohort 25 23.9 112
Highest exposure,
> 5 yr employment 12 8.5 144
Buffler et al. (10)d Lung
Total cohort 5 1.7 289a
Long exposure duration 4 1.05 381a
Short exposure duration 0 0.45
Ott et al. (11) Respiratory
Total cohort 7 5.8 121
EEH (12) Respiratory
Total cohort 45 44.3 107
Highest exposure 7 5.1 141
Medium exposure 19 17.0 116
Low exposure 19 22.2 92
ap < 0.05.
bProportional mortality study risk ratio.
Table 4. Epidemiologic study results ofVC-exposed workers as related to lymphatic and hematopoietic system cancer deaths.
Deaths
Investigation Sitea Observed Expected SMR
Waxweiler et al. (5) (200-205) 4 2.50 159
Latency > 15 yr (200-205) 3 1.70 176
Fox and Collier (7) (200-207) 9 9.01 100
Monson (8) (200-205) 5 3.4 1.5a
Tabershaw & Gaffey (9) (200-203, 205) 6 6.06 106
Highest exposure, > 5 years
employment 4 1.84 222
EEH (12) (200-203, 205) 11 10.36 112
Latency > 20 years 4 3.10 136
aInternational Classification of Diseases, 7th Revision.
bIntemational Classification of Diseases, 8th Revision.
cProportional mortality study risk ratio.
As shown in Table 3, data from the EEH (12) and
Buffler et al. (10) studies suggested a qualitative
dose-response relationship between VC exposure
and lung cancer risk. However, retrospective cate-
gorization of high, medium and low exposure, as
was used in the EEH study (12), must be viewed
with caution because of the subjective nature of
October 1981
judgment. The study by Buffler et al. (10) is
particularly noteworthy; within a small cohort of
only 464 workers, a fourfold risk oflung cancer was
observed. When the investigators examined the
effect of smoking, under the extreme assumption
that those with unknown smoking habits were
smokers, the data still demonstrated a significant
93excess of lung cancer (5 observed versus 1.98
expected.)
Cancer of the Lymphatic and
Hematopoietic System in Humans
Table 4 summarizes data on cancer of the lym-
phatic and hematopoietic systems among workers
exposed to VC. The relative risks for various
studies ranged from 1.0 to 2.2, and none of the
results demonstrated a significant excess. Although
somewhat suggestive, the data need to be further
analyzed by latency period and exposure levels
combined. Analysis of data separately for lym-
phatic cancers and leukemia might also lead to
meaningful observations.
Summary
Insummary, epidemiologicevidencedemonstrates
that the carcinogenic effects of VC in humans
extend beyond the liver. The brain and lung should
also be considered target organs. Some studies
indicate that the lymphatic and hematopoietic sys-
tems are also involved. These observations in
humans are supported by studies demonstrating
the induction of cancer of these same sites in
experimental animals.
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